This single-centre observational study included 22 consecutive patients receiving percutaneous axillary intra-aortic balloon pumps between December 2020 and December 2023. All had refractory heart failure and were listed for heart transplantation; mean age was 53 years. Implantation succeeded in all selected patients, with median support lasting 15 days (interquartile range 7–28). Device migration occurred in 18.2% and limb ischemia in 9.1%, with isolated infectious and neurological events also reported. Half underwent transplantation or were successfully weaned from mechanical support.
This small series documents successful axillary IABP implantation in selected transplant-listed patients, alongside device-related complications. Without a comparator, it does not establish comparative safety or clinical benefit.
Study limitation: The small, single-centre cohort lacked a comparator, limiting conclusions about comparative outcomes and safety.
AI-generated from the published abstract with automated source checks. For research discovery; consult the original paper before applying findings.